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DNA testing is recommended in families fulfilling at
least “suspected HNPCC” criteria. After exclusion of
FAP (characteristic FAP features include polyposis,
congenital hypertrophy of the retinal pigment epithelium,
cysts and osteomata of bones of the maxilla and
mandible, desmoid tumours), immunohistochemical
analyses (IHC) of MLH1, MSH2 and MSH6 expression
in malignant tissues should be performed (absence of
the protein may indicate the mutated gene).
The results of several studies performed in our
centre characterised the frequencies and spectrum of
MSH2 and MLH1 mutations in Poland [1]. Similarly to
other populations, the most frequent causes of HNPCC
in Poland are MLH1 and MSH2 mutations, constituting
90% of all mutations associated with this syndrome.
MLPA detects 10% of these mutations. In over 60% of
all HNPCC families recurrent mutations can be found.
Thus after IHC, MLPA for MSH2 and MLH1 should be
performed. Next, with MLPA negative, DNA tests
searching for recurrent mutations, characteristic for the
Polish population, should be applied. The last step
should include DHPLC [2] and sequencing of the cases
indicated by DHPLC results.
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